Assessment of potential biomarkers for early detection and management of Glomerulonephritis patients with diabetic diseases

• Published in: American journal of clinical pathology 2023-11, Vol.160 (Supplement_1), p.S18-S19
• Main Authors: Addissouky, T A, Khalil, A A, El Agroudy, A E
• Format: Article
• Language: English
• Subjects: Biomarkers; Biopsy; Complement activation; Complement component C3; Creatinine; Cystatins; Cytokines; Diabetes; Diabetes mellitus; Dialysis; Exosomes; Glomerulonephritis; Interleukin 6; Kidney diseases; MicroRNAs; miRNA; Renal failure; Tumor necrosis factor-TNF; Tumor necrosis factor-α
• ISSN: 0002-9173; 1943-7722
• DOI: 10.1093/ajcp/aqad150.040

Abstract Introduction/Objective Glomerulonephritis is a serious kidney disease that can lead to kidney failure if not detected and treated early. Several potential biomarkers have been identified to aid in early detection of this condition. it is important to investigate and validate these novel biomarkers to improve patient outcomes in the management of glomerulonephritis. Methods/Case Report The various biomarkers such as Creatinine, urinary exosomes, Cystatin-C, interleukin-6, tumor necrosis factor-alpha (TNF-α), Fasting blood glucose, Albumin, MicroRNAs, and complement activation factors (C3, C4d) were measured and calculated in 98 infected cases with diabetic patients who had acute kidney diseases. The same biomarkers had been implemented for 87 cases with chronic renal disease on dialysis. Also, the same parameters were determined in 82 healthy persons as controls. Alternative markers' levels were determined by using Microscopic, Biochemical, ELISA, and RT-PCR techniques. The biopsy had been applied only to infected patients. Imaging diagnostic tools have been applied to all cases. Results (if a Case Study enter NA) The studied biomarkers have high sensitivity from 81.35% to 94.72% and accuracy from 88.76% to 96.83% as well as their cut off which approved the aim of this study. Thereafter, the studied markers' reports assisted in detecting glomerulonephritis diseases at early stages. Conclusion Alternative biomarkers (Cystatin-C, interleukin-6, tumor necrosis factor-alpha (TNF-α), urinary exosomes, MicroRNAs, and complement activation factors (C3, C4d)) are considered as prospective markers to differentiate healthy individuals from chronic kidney disease by their significant results. Hence, if the studied biomarker has been measured regularly for outpatients who complain of renal diseases, that can be assisted in the early detection of kidney diseases, including glomerulonephritis, and then it can be well managed.